Improving Survival in Metastatic Colorectal Cancer Through Optimized Patient Selection

Abstract: The systemic treatment options for patients with metastatic colorectal cancer have recently expanded with the US Food and Drug Administration approval of fruquintinib being added to […]

Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]

Highlights in Colorectal Cancer

Neoadjuvant Chemotherapy Allows Most Patients With Locally Advanced Rectal Cancer to Skip Pelvic Chemoradiation The phase 3 PROSPECT trial found that the addition of neoadjuvant chemotherapy […]

The Use of Immunotherapy in Metastatic Microsatellite-Stable Colorectal Cancer

H&O What percentage of cases of metastatic colorectal cancer (CRC) fall into the microsatellite-stable (MSS) category? CL Approximately 95% to 96% of patients with metastatic CRC […]

Who Is a Candidate for Nonoperative Management of Early-Stage Rectal Cancer?

H&O What is standard treatment for early-stage rectal cancer? CH Surgery is the standard treatment for early-stage rectal cancer. In patients with T1N0 disease, the standard […]

Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification

H&O How common is HER2 amplification in metastatic colorectal cancer (CRC)? KR HER2 amplification is seen in approximately 2% to 3% of unselected patients with CRC. […]

Optimizing Administration of Third-Line Treatment in Metastatic Colorectal Cancer

Abstract: The past decade has seen substantial improvements in outcomes among patients with metastatic colorectal cancer treated with first and second lines of therapy. An increasing number […]

The Emergence of Targetable Pathways in Colorectal Cancer

Abstract: Colorectal cancer continues to be one of the leading causes of cancer-related morbidity and mortality globally. Despite an overall decreasing incidence of the disease, early-onset […]

How Quality of Life Can Inform Management Decisions in Later-Line Metastatic Colorectal Cancer

Abstract: For many years, the focus of treatment in patients with metastatic colorectal cancer has been to prolong patient survival. Increasing evidence, however, highlights the quality-of-life issues […]

Highlights in Colorectal Cancer From the 2021 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2021 ASCO Annual Meeting • June 4-8, 2021 Final Overall Survival for the Phase III KN177 Study: Pembrolizumab […]

Cases in the Management of Metastatic Colorectal Cancer: Regorafenib as Second-Line Therapy After FOLFOXIRI Plus Bevacizumab in a Patient With a KRAS Mutation

Regorafenib as Second-Line Therapy After FOLFOXIRI Plus Bevacizumab in a Patient With a KRAS Mutation Tanios S. Bekaii-Saab, MD Patient Case A 53-year-old woman presented […]

Considerations in the Management of Younger Patients With Colorectal Cancer

Abstract: The incidence of colorectal cancer in patients ages 18 to 49 years has increased by 51% throughout the past 3 decades. In the United States, recent […]

Cases in the Management of Metastatic Colorectal Cancer: Rechallenge With Chemotherapy After Regorafenib in a Patient With RAS/BRAF Wild-Type Disease

CASE 3 OF A 3-PART SERIES Patient Case The patient is a 50-year-old man who had been diagnosed with left-sided colon cancer 4 years earlier […]

Cases in the Management of Metastatic Colorectal Cancer: Use of Regorafenib as a Bridge to Chemotherapy

Case 2 of a 3-Part Series Patient Case The patient is a 62-year-old man with a long history of metastatic colorectal cancer (mCRC). His primary […]

Transitioning From Second-Line to Third-Line Therapy in Metastatic Colorectal Cancer

Abstract: In the setting of metastatic colorectal cancer, many gains in patient outcomes have been achieved throughout the last 2 decades. A primary driver of these gains […]

Cases in the Management of Metastatic Colorectal Cancer: Sequencing Therapies in a Patient With the BRAF V600E Mutation

Case 1 of a 3-Part Series Sequencing Therapies in a Patient With the BRAF V600E Mutation Tanios S. Bekaii-Saab, MD Patient Case The patient […]

How to Incorporate a Chemo-Free Interval Into the Management of Metastatic Colorectal Cancer

Abstract: Management of metastatic colorectal cancer reflects a continuum of care. The primary treatment goals are to prolong survival while maintaining the best quality of life. The […]

Optimizing the Treatment Sequence From Second-Line to Third-Line Therapy in Patients With Metastatic Colorectal Cancer

Abstract: In clinical trials of metastatic colorectal cancer, progressive disease after second-line therapy is often defined according to Response Evaluation Criteria in Solid Tumors criteria. In the […]

The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician

Abstract: In 2012, the US Food and Drug Administration approved the kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer who have been previously […]

Sequencing Beyond the Second-Line Setting in Metastatic Colorectal Cancer

Abstract: The standard treatment for patients with metastatic colorectal cancer (mCRC) in the first- and second-line setting is generally chemotherapy, which can be augmented with vascular […]